- Home
- DNLI vs VRDN Comparison
DNLI vs VRDN Comparison
Compare DNLI & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNLI | VRDN |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DNLI | VRDN |
|---|---|---|
| Price | $20.94 | $28.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $30.80 | ★ $41.42 |
| AVG Volume (30 Days) | ★ 1.6M | 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | $26,080.80 |
| Revenue Next Year | $3,886.00 | $2.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.57 | $9.90 |
| 52 Week High | $23.77 | $34.29 |
Technical Indicators
Market Signals| Indicator | DNLI | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 57.99 | 43.42 |
| Support Level | $13.29 | $21.50 |
| Resistance Level | $23.77 | $33.71 |
| Average True Range (ATR) | 1.20 | 1.29 |
| MACD | -0.05 | -0.16 |
| Stochastic Oscillator | 69.29 | 37.91 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).